Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-VestGlobeNewsWire • 06/14/23
Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual MeetingGlobeNewsWire • 06/08/23
Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023GlobeNewsWire • 05/30/23
Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical TrialsGlobeNewsWire • 05/02/23
Plus Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 04/20/23
Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a TrialGlobeNewsWire • 04/19/23
Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual ConferenceGlobeNewsWire • 04/18/23
Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal MetastasesGlobeNewsWire • 04/18/23
Plus Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on April 20, 2023GlobeNewsWire • 04/12/23
Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a TrialGlobeNewsWire • 03/28/23
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal MetastasesGlobeNewsWire • 03/22/23
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsGlobeNewsWire • 02/23/23
Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023GlobeNewsWire • 02/14/23
Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹⁸⁶Re) Obisbemeda for the Treatment of Leptomeningeal MetastasesGlobeNewsWire • 02/01/23
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent GlioblastomaGlobeNewsWire • 01/18/23
Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-OncologyGlobeNewsWire • 11/19/22
Plus Therapeutics to Provide Update on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-OncologyGlobeNewsWire • 11/02/22
Plus Therapeutics Announces Selection of “Rhenium (186Re) Obisbemeda” as International Non-Proprietary Name for 186RNLGlobeNewsWire • 10/26/22